UK R&D Centre for Antimicrobial Resistance Goes Into Battle
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.
You may also be interested in...
Buzz Grows Around Biotech At Former AstraZeneca Campus
Chris Doherty, managing director of the UK's Alderley Park, tells Scrip that the departure of the drug giant from its global R&D headquarters has acted as a catalyst to create a vibrant biotech cluster that is attractive to local, national and international companies.
AMR Roundtable: Optimism About CARB-X's Success And Prospects For The Future (Part 2)
The Pink Sheet spoke with CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about incentives for antibiotic and antifungal drug development, including a lengthy discussion of the US BARDA's CARB-X accelerator, including ideas for expanding geographically and by product type.
Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review
Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.